LivaNova’s (LIVN) Buy Rating Reiterated at Needham & Company LLC

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating restated by investment analysts at Needham & Company LLC in a report released on Wednesday, Benzinga reports. They presently have a $72.00 target price on the stock. Needham & Company LLC’s price target points to a potential upside of 15.70% from the company’s previous close.

A number of other equities research analysts have also commented on LIVN. Mizuho restated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a report on Wednesday, March 27th. Barclays raised their price objective on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Robert W. Baird raised their price objective on shares of LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, February 22nd. Finally, StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $64.40.

LivaNova Trading Up 11.6 %

LIVN traded up $6.48 during mid-day trading on Wednesday, hitting $62.23. The stock had a trading volume of 1,604,836 shares, compared to its average volume of 628,205. The stock’s fifty day simple moving average is $54.32 and its 200-day simple moving average is $50.77. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. The firm has a market capitalization of $3.37 billion, a price-to-earnings ratio of 192.91 and a beta of 0.89. LivaNova has a 1-year low of $42.75 and a 1-year high of $62.38.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.10. The company had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. During the same period last year, the business posted $0.81 earnings per share. As a group, research analysts forecast that LivaNova will post 3.01 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. increased its stake in LivaNova by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 231,666 shares of the company’s stock valued at $12,959,000 after buying an additional 6,281 shares during the last quarter. New York State Teachers Retirement System grew its position in shares of LivaNova by 0.3% in the 1st quarter. New York State Teachers Retirement System now owns 64,322 shares of the company’s stock valued at $3,598,000 after acquiring an additional 200 shares during the period. Louisiana State Employees Retirement System grew its position in shares of LivaNova by 2.6% in the 1st quarter. Louisiana State Employees Retirement System now owns 15,500 shares of the company’s stock valued at $867,000 after acquiring an additional 400 shares during the period. State of Michigan Retirement System grew its position in shares of LivaNova by 2.3% in the 1st quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock valued at $739,000 after acquiring an additional 300 shares during the period. Finally, Diversified Trust Co grew its position in shares of LivaNova by 6.6% in the 1st quarter. Diversified Trust Co now owns 12,890 shares of the company’s stock valued at $721,000 after acquiring an additional 796 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.